Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
103.11
-0.37 (-0.36%)
Jul 16, 2025, 3:11 PM - Market open
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiology | 8.90B | 8.35B | 7.80B | 7.32B | 6.97B | 6.71B | 6.49B | 6.32B | |||||||||||
| Cardiology Growth | 27.65% | 24.40% | 20.24% | 15.81% | 13.75% | 13.08% | 11.35% | 11.08% | |||||||||||
| Endoscopy | 2.72B | 2.69B | 2.64B | 2.59B | 2.55B | 2.48B | 2.41B | 2.34B | |||||||||||
| Endoscopy Growth | 6.67% | 8.22% | 9.68% | 10.86% | 12.35% | 11.75% | 9.06% | 7.15% | |||||||||||
| Peripheral Interventions | 2.49B | 2.41B | 2.30B | 2.23B | 2.18B | 2.11B | 2.05B | 1.99B | |||||||||||
| Peripheral Interventions Growth | 14.41% | 14.27% | 11.99% | 12.09% | 12.55% | 11.12% | 8.92% | 7.32% | |||||||||||
| Urology | 2.32B | 2.20B | 2.10B | 2.05B | 2.01B | 1.96B | 1.91B | 1.86B | |||||||||||
| Urology Growth | 15.54% | 12.02% | 9.56% | 9.87% | 9.79% | 10.77% | 10.19% | 10.43% | |||||||||||
| Neuromodulation | 1.12B | 1.11B | 1.08B | 1.04B | 998.00M | 976.00M | 956.00M | 948.00M | |||||||||||
| Neuromodulation Growth | 12.22% | 13.22% | 12.45% | 9.28% | 5.83% | 6.32% | 4.71% | 3.83% |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 10.91B | 10.21B | 9.53B | 9.04B | 8.68B | 8.43B | 8.20B | 8.03B | |||||||||||
| United States Growth | 25.71% | 21.19% | 16.25% | 12.49% | 10.49% | 10.40% | 10.14% | 11.03% | |||||||||||
| EMEA | 3.27B | 3.23B | 3.15B | 3.05B | 2.95B | 2.86B | 2.76B | 2.68B | |||||||||||
| EMEA Growth | 11.03% | 13.06% | 13.90% | 13.75% | 12.70% | 13.02% | 9.17% | 5.56% | |||||||||||
| APAC | 2.74B | 2.69B | 2.62B | 2.54B | 2.50B | 2.40B | 2.32B | 2.24B | |||||||||||
| APAC Growth | 9.56% | 11.83% | 12.75% | 13.47% | 16.50% | 13.52% | 8.56% | 5.61% | |||||||||||
| LACA | 631.00M | 625.00M | 618.00M | 605.00M | 583.00M | 560.00M | 534.00M | 507.00M | |||||||||||
| LACA Growth | 8.23% | 11.61% | 15.73% | 19.33% | 19.71% | 19.66% | 17.88% | 17.09% |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative | 6.22B | 5.98B | 5.75B | 5.43B | 5.34B | 5.19B | 4.97B | 4.86B | |||||||||||
| Selling, General, and Administrative Growth | 16.45% | 15.30% | 15.62% | 11.66% | 14.20% | 14.82% | 10.29% | 9.45% | |||||||||||
| Research and Development | 1.69B | 1.62B | 1.52B | 1.47B | 1.44B | 1.42B | 1.38B | 1.37B | |||||||||||
| Research and Development Growth | 17.24% | 14.20% | 9.91% | 7.55% | 7.68% | 6.95% | 5.26% | 6.31% | |||||||||||
| Amortization | 862.00M | 857.00M | 840.00M | 843.00M | 840.00M | 829.00M | 820.00M | 814.00M | |||||||||||
| Amortization Growth | 2.62% | 3.38% | 2.44% | 3.56% | 3.96% | 3.24% | 3.02% | 4.63% | |||||||||||
| Asset and Goodwill Impairment | - | 387.00M | - | 277.00M | - | - | 58.00M | 182.00M | |||||||||||
| Asset and Goodwill Impairment Growth | - | - | - | 52.20% | - | - | -82.37% | -45.18% | |||||||||||
| Royalty Expense | 38.00M | 34.00M | 36.00M | 42.00M | 45.00M | 46.00M | 47.00M | 47.00M | |||||||||||
| Royalty Expense Growth | -15.56% | -26.09% | -23.40% | -10.64% | -2.17% | -2.13% | 4.44% | -2.08% | |||||||||||
| Restructuring Net Charges | 23.00M | 16.00M | 31.00M | 38.00M | 53.00M | 70.00M | 57.00M | 46.00M | |||||||||||
| Restructuring Net Charges Growth | -56.60% | -77.14% | -45.61% | -17.39% | 29.27% | 180.00% | 35.71% | -2.13% | |||||||||||
| Litigation-related Net Charges | - | - | - | - | - | - | 20.00M | - | |||||||||||
| Contingent Consideration Net Expense | -17.00M | -5.00M | 10.00M | 45.00M | 62.00M | 57.00M | 10.00M | 18.00M | |||||||||||
| Contingent Consideration Net Expense Growth | - | - | - | 150.00% | 77.14% | 62.86% | -80.00% | 350.00% |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.